Evidence map›Paper›PMID 28573530›Full record

ArticleInflammation2017

MeCP2 Regulates PTCH1 Expression Through DNA Methylation in Rheumatoid Arthritis.

Zheng-Hao Sun, Yan-Hui Liu, Jun-da Liu, Dan-Dan Xu, Xiao-Feng Li, Xiao-Ming Meng, Tao-Tao Ma, Cheng Huang, Jun Li

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Zheng-Hao SunSchool of Pharmacy, The Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, Anhui Medical University, Meishan Road No. 81, Hefei, Anhui Province, 230032, China.
Yan-Hui LiuSchool of Pharmacy, The Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, Anhui Medical University, Meishan Road No. 81, Hefei, Anhui Province, 230032, China.
Jun-da LiuSchool of Pharmacy, The Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, Anhui Medical University, Meishan Road No. 81, Hefei, Anhui Province, 230032, China.
Dan-Dan XuSchool of Pharmacy, The Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, Anhui Medical University, Meishan Road No. 81, Hefei, Anhui Province, 230032, China.
Xiao-Feng LiSchool of Pharmacy, The Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, Anhui Medical University, Meishan Road No. 81, Hefei, Anhui Province, 230032, China.
Xiao-Ming MengSchool of Pharmacy, The Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, Anhui Medical University, Meishan Road No. 81, Hefei, Anhui Province, 230032, China.
Tao-Tao MaSchool of Pharmacy, The Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, Anhui Medical University, Meishan Road No. 81, Hefei, Anhui Province, 230032, China.
Cheng HuangSchool of Pharmacy, The Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, Anhui Medical University, Meishan Road No. 81, Hefei, Anhui Province, 230032, China.
Jun LiSchool of Pharmacy, The Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, Anhui Medical University, Meishan Road No. 81, Hefei, Anhui Province, 230032, China. lj@ahmu.edu.cn.
Ministry of Education of the People's Republic of China · CNAnhui Medical University · CN

Funding

Anhui Provincial Natural Science Foundation 21408085MKL31National Natural Science Foundation of China 81273526National Natural Science Foundation of China 81473268the Key fund project of Anhui Education Department KJ2016A364the Key fund project of Anhui Education Department KJ2016A365
6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease, in which pathogenesis is not clear. Many research demonstrated that fibroblast-like synoviocytes (FLSs) play a key role in RA pathogenesis, join in the cartilage injury and hyperplasia of the synovium, and contribute to the release of inflammatory cytokines. We used adjuvant arthritis (AA) rats as RA animal models. The methyl-CpG-binding protein 2 (MeCP2) enables the suppressed chromatin structure to be selectively detected in AA FLSs. Overexpression of this protein leads to an increase of integral methylation levels. Some research has confirmed the hedgehog (Hh) signaling pathway plays an important role in RA pathogenesis; furthermore, patched 1 (PTCH1) is a negative fraction of Hh signaling pathway. We used 5-aza-2'-deoxycytidine (5-azadc) as DNA methylation inhibitor. In our research, we found MeCP2 reduced PTCH1 expression in AA FLSs; 5-azadc obstructed the loss of PTCH1 expression. 5-Azadc, treatment of AA FLSs, also blocks the release of inflammatory cytokines. In order to probe the potential molecular mechanism, we assumed the epigenetic participation in the regulation of PTCH1. Results demonstrated that PTCH1 hypermethylation is related to the persistent FLS activation and inflammation in AA rats. Knockdown of MeCP2 using small-interfering RNA technique added PTCH1 expression in AA FLSs. Our results indicate that DNA methylation may offer molecule mechanisms, and the reduced PTCH1 methylation level could regulate inflammation through knockdown of MeCP2. Graphical Abstract PTCH1 is an inhibitory protein of the Hedgehog signaling pathway. Increased expression of PTCH1 can inhibit the expression of Gli1 and Shh, thereby inhibiting the activation of Hedgehog signaling pathway. Inactivated Hedgehog signaling pathway inhibits the secretion of IL-6 and TNF-α. MeCP2 mediates hypermethylation of PTCH1 gene and decreases the expression of PTCH1 protein, thus activating Hedgehog signaling pathway and increasing secretion of IL-6 and TNF-α.

Indexed as

DNA MethylationAnimalsArthritis, RheumatoidHedgehog ProteinsInterleukin-6Methyl-CpG-Binding Protein 2Patched-1 ReceptorRatsSignal TransductionSynoviocytesTumor Necrosis Factor-alphaHedgehog ProteinsInterleukin-6Methyl-CpG-Binding Protein 2Patched-1 ReceptorPtch1 protein, ratTumor Necrosis Factor-alphaDNA methylationfibroblast-like synoviocyteshedgehog signaling pathwayinflammationmethyl-CpG-binding protein 2PTCH1rheumatoid arthritis

Identifiers

PMID28573530
OpenAlexW2620603030

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.